<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03556137</url>
  </required_header>
  <id_info>
    <org_study_id>45332</org_study_id>
    <nct_id>NCT03556137</nct_id>
  </id_info>
  <brief_title>PET/MRI in the Diagnosis of Chronic Pain</brief_title>
  <official_title>Use of [18F]FTC-146 PET/MRI in the Diagnosis of Chronic Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GE Healthcare</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Several studies have implicated involvement of sigma-1 receptors (SR1s) in the generation of
      chronic pain, while others are investigating anti SR1 drugs for treatment of chronic pain.
      Using [18F]-FTC-146 and positron emission tomography/magnetic resonance imaging (PET/MRI),
      the investigators hope to identify the source of pain generation in patients with chronic
      pain. The purpose of this study is to compare the uptake of [18F]FTC-146 in healthy
      volunteers to that of individuals suffering from chronic pain.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic pain is a significant, widespread problem affecting every fifth person worldwide.
      Reported in 2011 by the Institute of Medicine, chronic pain affects 116 million American
      adults - more than the total number of individuals affected by heart disease, cancer, and
      diabetes combined. An estimated $635 billion each year is spent in the medical management of
      chronic pain and lost productivity. Better clinical methods to diagnose and localize pain are
      needed.

      The investigators have developed a S1R-specific radiotracer, [18F]FTC-146. Using imaging
      approaches to assess the location of S1R in pain may provide a tool to diagnose pain
      generators, monitor treatment response, and aid in the selection of patients for treatment.

      The goal is to use [18F]FTC-146 to image S1R expression in healthy volunteers and to compare
      the images to those individuals suffering from pain conditions in the following categories:
      (1) nociceptive pain (pain that results from tissue injury or inflammation), (2) neuropathic
      pain (pain that results from direct injury, disruption, impingement/compression or
      malfunction of the peripheral and/or central nervous system), and (3) mixed pain (pain that
      appears to have both nociceptive and neuropathic).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 16, 2018</start_date>
  <completion_date type="Anticipated">June 2024</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>[18F]FTC-146 Biodistribution in Healthy Volunteers</measure>
    <time_frame>Estimated average of 3 hours</time_frame>
    <description>Biodistribution of [18F]FTC-146 represented as Standardized Uptake Value max (SUVmax) in healthy volunteers.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>[18F]FTC-146 Biodistribution in Pain Patients</measure>
    <time_frame>Estimated average of 3 hours</time_frame>
    <description>Biodistribution of [18F]FTC-146 represented as Standardized Uptake Value max (SUVmax) in pain patients.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">144</enrollment>
  <condition>Neuropathic Pain</condition>
  <condition>Nociceptive Pain</condition>
  <condition>MIxed Pain (Nociceptive and Neuropathic)</condition>
  <arm_group>
    <arm_group_label>Pain Patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Individuals suffering from nociceptive pain, neuropathic pain, and mixed pain (pain that appears to be both nociceptive and neuropathic) and undergo a [18F]FTC-146 PET/MRI scan.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Volunteers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Individuals who do not have pain and undergo a [18F]FTC-146 PET/MRI scan.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[18F]FTC-146</intervention_name>
    <description>Adult participants will be injected with 5-10 mCi of [18F]FTC-146 and undergo a PET/MRI scan.</description>
    <arm_group_label>Healthy Volunteers</arm_group_label>
    <arm_group_label>Pain Patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Healthy Volunteers:

        1. At least 18 years old.

        Pain Patients:

          1. At least 18 years old.

          2. Chronic pain (nociceptive, neuropathic or mixed pain) lasting greater than 2 months.

          3. Pain level of at least 4/10 on a 0-10 Comparative Pain Scale.

        Exclusion Criteria:

        Healthy Volunteers:

          1. Pain

          2. Pain Medication

          3. MRI incompatible

          4. Pregnant or nursing

          5. Non-English speaker

        Pain Patients:

          1. MRI incompatible

          2. Pregnant or nursing

          3. Non-English speaker
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sandip Biswal, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University Department of Radiology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Peter W Cipriano, BA</last_name>
    <phone>6503803782</phone>
    <email>pciprian@stanford.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter W Cipriano, BA</last_name>
      <phone>650-380-3782</phone>
      <email>pciprian@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Sandip Biswal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Shen B, Behera D, James ML, Reyes ST, Andrews L, Cipriano PW, Klukinov M, Lutz AB, Mavlyutov T, Rosenberg J, Ruoho AE, McCurdy CR, Gambhir SS, Yeomans DC, Biswal S, Chin FT. Visualizing Nerve Injury in a Neuropathic Pain Model with [(18)F]FTC-146 PET/MRI. Theranostics. 2017 Jul 8;7(11):2794-2805. doi: 10.7150/thno.19378. eCollection 2017.</citation>
    <PMID>28824716</PMID>
  </reference>
  <reference>
    <citation>Hjørnevik T, Cipriano PW, Shen B, Park JH, Gulaka P, Holley D, Gandhi H, Yoon D, Mittra ES, Zaharchuk G, Gambhir SS, McCurdy CR, Chin FT, Biswal S. Biodistribution and Radiation Dosimetry of (18)F-FTC-146 in Humans. J Nucl Med. 2017 Dec;58(12):2004-2009. doi: 10.2967/jnumed.117.192641. Epub 2017 Jun 1.</citation>
    <PMID>28572487</PMID>
  </reference>
  <reference>
    <citation>Shen B, Park JH, Hjørnevik T, Cipriano PW, Yoon D, Gulaka PK, Holly D, Behera D, Avery BA, Gambhir SS, McCurdy CR, Biswal S, Chin FT. Radiosynthesis and First-In-Human PET/MRI Evaluation with Clinical-Grade [(18)F]FTC-146. Mol Imaging Biol. 2017 Oct;19(5):779-786. doi: 10.1007/s11307-017-1064-z.</citation>
    <PMID>28280965</PMID>
  </reference>
  <reference>
    <citation>Shen B, James ML, Andrews L, Lau C, Chen S, Palner M, Miao Z, Arksey NC, Shuhendler AJ, Scatliffe S, Kaneshige K, Parsons SM, McCurdy CR, Salehi A, Gambhir SS, Chin FT. Further validation to support clinical translation of [(18)F]FTC-146 for imaging sigma-1 receptors. EJNMMI Res. 2015 Dec;5(1):49. doi: 10.1186/s13550-015-0122-2. Epub 2015 Sep 17.</citation>
    <PMID>26384292</PMID>
  </reference>
  <reference>
    <citation>James ML, Shen B, Nielsen CH, Behera D, Buckmaster CL, Mesangeau C, Zavaleta C, Vuppala PK, Jamalapuram S, Avery BA, Lyons DM, McCurdy CR, Biswal S, Gambhir SS, Chin FT. Evaluation of σ-1 receptor radioligand 18F-FTC-146 in rats and squirrel monkeys using PET. J Nucl Med. 2014 Jan;55(1):147-53. doi: 10.2967/jnumed.113.120261. Epub 2013 Dec 12.</citation>
    <PMID>24337599</PMID>
  </reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>June 2, 2018</study_first_submitted>
  <study_first_submitted_qc>June 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 14, 2018</study_first_posted>
  <last_update_submitted>March 6, 2020</last_update_submitted>
  <last_update_submitted_qc>March 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Sandip Biswal</investigator_full_name>
    <investigator_title>Associate Professor of Radiology</investigator_title>
  </responsible_party>
  <keyword>PET/MRI</keyword>
  <keyword>Chronic Pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuralgia</mesh_term>
    <mesh_term>Chronic Pain</mesh_term>
    <mesh_term>Nociceptive Pain</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

